Healthcare provider profile · identity verified

Mickey E. Denen, MD

Internal Medicine · DAYTON, OH · NPI 1639118284

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	364	98
Atorvastatin Calcium	Atorvastatin Calcium	344	97
Levothyroxine Sodium	Levothyroxine Sodium	335	94
Amlodipine Besylate	Amlodipine Besylate	269	75
Losartan Potassium	Losartan Potassium	211	62
Omeprazole	Omeprazole	182	56
Lisinopril	Lisinopril	172	47
Metoprolol Succinate	Metoprolol Succinate	163	53
Montelukast Sodium	Montelukast Sodium	137	25
Furosemide	Furosemide	130	46
Metformin Hcl	Metformin Hcl	128	28
Gabapentin	Gabapentin	124	23
Pantoprazole Sodium	Pantoprazole Sodium	118	33
Metoprolol Tartrate	Metoprolol Tartrate	110	32
Famotidine	Famotidine	95	34
Escitalopram Oxalate	Escitalopram Oxalate	87	26
Fluticasone Propionate	Fluticasone Propionate	79	35
Metformin Hcl Er	Metformin Hcl	72	24
Valsartan	Valsartan	70	19
Simvastatin	Simvastatin	69	17
Farxiga	Dapagliflozin Propanediol	68	14
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	68	17
Tamsulosin Hcl	Tamsulosin Hcl	68	26
Synthroid	Levothyroxine Sodium	59	18
Sertraline Hcl	Sertraline Hcl	56	19
Glimepiride	Glimepiride	55	13
Lorazepam	Lorazepam	54	12
Clopidogrel	Clopidogrel Bisulfate	51	16
Ezetimibe	Ezetimibe	50	17
Hydroxyzine Hcl	Hydroxyzine Hcl	50	11
Indapamide	Indapamide	49	15
Albuterol Sulfate Hfa	Albuterol Sulfate	48	27
Allopurinol	Allopurinol	47	15
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	47	13
Carvedilol	Carvedilol	45	13
Meloxicam	Meloxicam	45	19
Warfarin Sodium	Warfarin Sodium	43	suppressed
Breo Ellipta	Fluticasone/Vilanterol	40	14
Duloxetine Hcl	Duloxetine Hcl	40	17
Trazodone Hcl	Trazodone Hcl	39	13
Buspirone Hcl	Buspirone Hcl	38	11
Baclofen	Baclofen	37	20
Clonazepam	Clonazepam	36	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	36	suppressed
Bupropion Xl	Bupropion Hcl	35	suppressed
Alprazolam	Alprazolam	34	suppressed
Ozempic	Semaglutide	34	11
Spironolactone	Spironolactone	33	12
Hydrochlorothiazide	Hydrochlorothiazide	32	suppressed
Memantine Hcl	Memantine Hcl	32	suppressed
Finasteride	Finasteride	31	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	31	11
Eliquis	Apixaban	30	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Pravastatin Sodium	Pravastatin Sodium	30	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	29	20
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	29	12
Prednisone	Prednisone	29	20
Amitriptyline Hcl	Amitriptyline Hcl	28	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	28	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Pregabalin	Pregabalin	27	suppressed
Trulicity	Dulaglutide	27	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	26	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	26	21
Oxybutynin Chloride Er	Oxybutynin Chloride	26	suppressed
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Gemfibrozil	Gemfibrozil	25	suppressed
Glipizide Er	Glipizide	25	suppressed
Tizanidine Hcl	Tizanidine Hcl	25	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	24	suppressed
Benazepril Hcl	Benazepril Hcl	22	suppressed
Carbamazepine Er	Carbamazepine	22	suppressed
Tramadol Hcl	Tramadol Hcl	22	suppressed
Testosterone	Testosterone	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	20	suppressed
Methylprednisolone	Methylprednisolone	20	19
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Atenolol	Atenolol	19	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	19	suppressed
Mounjaro	Tirzepatide	19	suppressed
Cefdinir	Cefdinir	18	15
Donepezil Hcl	Donepezil Hcl	18	suppressed
Nabumetone	Nabumetone	18	suppressed
Terazosin Hcl	Terazosin Hcl	18	suppressed
Verapamil Er	Verapamil Hcl	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Ibandronate Sodium	Ibandronate Sodium	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	15
Azelastine Hcl	Azelastine Hcl	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Doxepin Hcl	Doxepin Hcl	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	11
Bumetanide	Bumetanide	15	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Klor-Con M20	Potassium Chloride	15	suppressed
Acyclovir	Acyclovir	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	14	suppressed
Estradiol	Estradiol	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Methocarbamol	Methocarbamol	14	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	14	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Jantoven	Warfarin Sodium	13	suppressed
Jardiance	Empagliflozin	13	suppressed
Azithromycin	Azithromycin	12	11
Diltiazem 24hr Er	Diltiazem Hcl	12	suppressed
Fentanyl	Fentanyl	12	suppressed
Midodrine Hcl	Midodrine Hcl	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Temazepam	Temazepam	12	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error